A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with REGN2810 or isatuximab alone in patients with advanced malignancies

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with REGN2810 or isatuximab alone in patients with advanced malignancies

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.